Skip to content
Safe Wolverine

A versus-screen reading of the Wolverine peptide blend — BPC-157 and TB-500 racked side by side, every study and the regulatory-access record settled head-to-head.

06 / Studies behind the healing claims

What BPC-157 TB-500 references let you check about a claim

An aching tendon may make a claim of faster healing worth checking. Follow these links to studies and government explanations about pharmacy ingredients.

Read the study results plainlySee the government ingredient rules

What the small numbers beside claims lead to

Pain that won't ease may leave you wanting to check a healing claim. BPC-157 TB-500 references link claims to the papers that reported them. Studies [1]-[7] concern separate ingredients and changes inside cells. Reviews [8]-[10] discuss weak evidence and missing mixture tests. FDA pages [11]-[13] explain the rules for pharmacy-made medicine.

The small number beside a claim matches an entry below, whose link opens the paper. Longer codes marked DOI or PMID identify that paper in research libraries. Those paper codes differ from the small claim numbers.

You can check who received treatment and what changed.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. ↗
  6. Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. ↗
  7. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  8. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. (36 studies, 35 preclinical and 1 human; no clinical safety data; evidence level IV-V; no mention of TB-500 or combination use.) ↗
  9. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  10. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  11. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Former Category 2 entries for 'BPC-157' and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500', placed effective with the September 29, 2023 update to the nominated-substances list; shown as withdrawn nominations on the page current as of April 22, 2026.) ↗
  12. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the 503A/503B bulk-substance framework and bulks-list eligibility rules.) ↗
  13. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public calendar listing BPC-157 and TB-500 among bulk drug substances 'being considered for inclusion on the 503A Bulks List'; an advisory discussion, not a decision.) ↗
  14. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
  15. Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
  16. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
  17. et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗